pSivida Corp. Company Profile (NASDAQ:PSDV)

About pSivida Corp.

pSivida Corp. logopSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company's lead development product, Medidur is used for posterior of the eye (posterior uveitis). Medidur is in Phase III clinical trials. The Company's pre-clinical development program is focused on developing products using its platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat ophthalmic diseases, such as wet and dry age-related macular degeneration (AMD), glaucoma and osteoarthritis, among others. Its Durasert technology platform delivers therapeutics for predetermined periods of time ranging from days to years. Its Tethadur technology system utilizes BioSilicon, nanostructured elemental silicon, designed to provide sustained delivery of biologic molecules, such as peptides, proteins and antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PSDV
  • CUSIP:
Key Metrics:
  • Previous Close: $3.98
  • 50 Day Moving Average: $3.70
  • 200 Day Moving Average: $3.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.92
  • P/E Growth: 0.00
  • Market Cap: $136.00M
  • Outstanding Shares: 34,172,000
  • Beta: 1.52
Additional Links:
Companies Related to pSivida Corp.:

Analyst Ratings

Consensus Ratings for pSivida Corp. (NASDAQ:PSDV) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (75.88% upside)

Analysts' Ratings History for pSivida Corp. (NASDAQ:PSDV)
Show:
DateFirmActionRatingPrice TargetDetails
8/10/2016FBR & CoReiterated RatingBuyView Rating Details
12/29/2015Ladenburg ThalmannReiterated RatingBuyView Rating Details
12/17/2015Northland SecuritiesReiterated RatingBuyView Rating Details
7/7/2015MLV & Co.Reiterated RatingBuy$6.50View Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for pSivida Corp. (NASDAQ:PSDV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/7/2016        
5/5/2016Q3($0.20)($0.15)ViewN/AView Earnings Details
11/5/2015Q116($0.15)($0.17)ViewN/AView Earnings Details
9/9/2015Q415($0.14)($0.17)$409.00 millionViewN/AView Earnings Details
5/8/2015Q315($0.13)($0.17)ViewN/AView Earnings Details
2/5/2015($0.13)($0.14)ViewN/AView Earnings Details
11/7/2014Q3 14($0.12)$0.67$25.30 millionViewN/AView Earnings Details
9/9/2014Q414($0.15)($0.15)ViewN/AView Earnings Details
5/13/2014Q314($0.15)($0.03)$0.55 million$2.00 millionViewN/AView Earnings Details
2/7/2014Q214($0.13)($0.13)$430.00 million$0.59 millionViewN/AView Earnings Details
11/12/2013Q1($0.14)ViewListenView Earnings Details
9/25/2013Q413($0.12)($0.17)$0.65 million$0.49 millionViewN/AView Earnings Details
2/6/2013Q2 2013($0.11)$0.63 million$0.59 millionViewListenView Earnings Details
11/8/2012Q113($0.10)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for pSivida Corp. (NASDAQ:PSDV)
Current Year EPS Consensus Estimate: $-0.69 EPS
Next Year EPS Consensus Estimate: $-0.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for pSivida Corp. (NASDAQ:PSDV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for pSivida Corp. (NASDAQ:PSDV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2016Leonard S. RossVPSell5,000$4.70$23,500.00View SEC Filing  
12/22/2015Leonard S. RossVPSell33,950$5.39$182,990.50View SEC Filing  
12/22/2015Paul AshtonCEOSell120,000$5.39$646,800.00View SEC Filing  
10/1/2014Paul AshtonCEOSell10,000$4.27$42,700.00View SEC Filing  
9/2/2014Paul AshtonCEOSell10,000$4.78$47,800.00View SEC Filing  
8/1/2014Paul AshtonCEOSell10,000$4.37$43,700.00View SEC Filing  
7/1/2014Paul AshtonCEOSell10,000$4.32$43,200.00View SEC Filing  
6/19/2014Paul AshtonCEOSell7,000$4.00$28,000.00View SEC Filing  
6/17/2014Lori FreedmanVPSell7,900$4.00$31,600.00View SEC Filing  
6/17/2014Paul AshtonCEOSell7,700$4.00$30,800.00View SEC Filing  
6/13/2014Lori FreedmanVPSell11,700$4.02$47,034.00View SEC Filing  
6/13/2014Paul AshtonCEOSell11,800$4.02$47,436.00View SEC Filing  
10/1/2012Paul HopperDirectorBuy10,000$1.68$16,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for pSivida Corp. (NASDAQ:PSDV)
DateHeadline
streetinsider.com logopSivida (PSDV) Says Results from First Phase 3 Trial of Medidur Presented at ASRS (NASDAQ:PSDV)
www.streetinsider.com - August 16 at 7:05 PM
streetinsider.com logopSivida (PSDV) Says Results from First Phase 3 Trial of Medidur Presented at ASRS - StreetInsider.com (NASDAQ:PSDV)
www.streetinsider.com - August 16 at 10:13 AM
stocksdaily.net logoWill pSivida Corp. (NASDAQ:PSDV) Surprise Analysts This Quarter? - Stocks Daily (NASDAQ:PSDV)
www.stocksdaily.net - August 16 at 10:13 AM
finance.yahoo.com logoTopline Results from First Phase 3 Trial of pSivida’s Medidur™ Presented at ASRS Annual Meeting (NASDAQ:PSDV)
finance.yahoo.com - August 15 at 9:06 AM
investornewswire.com logoEarnings Surprise In Focus: pSivida Corp. (NASDAQ:PSDV) - Investor Newswire (NASDAQ:PSDV)
www.investornewswire.com - August 10 at 7:26 PM
4-traders.com logopSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle (NASDAQ:PSDV)
www.4-traders.com - August 10 at 10:03 AM
streetinsider.com logopSivida (PSDV) Says Medidur Inserter Utilization Study with Smaller-Diameter Needle Met Primary Endpoint (NASDAQ:PSDV)
www.streetinsider.com - August 10 at 10:03 AM
investors.com logopSivida Corp. achieves efficacy in uveitis trials with unique device (NASDAQ:PSDV)
www.proactiveinvestors.com.au - August 10 at 10:03 AM
streetinsider.com logopSivida (PSDV) Says Medidur Inserter Utilization Study with Smaller-Diameter Needle Met Primary Endpoint - StreetInsider.com (NASDAQ:PSDV)
www.streetinsider.com - August 9 at 7:13 PM
publicnow.com logoPrimary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle (NASDAQ:PSDV)
www.publicnow.com - August 9 at 7:13 PM
finance.yahoo.com logoPrimary Endpoint Met in pSivida’s Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle (NASDAQ:PSDV)
finance.yahoo.com - August 9 at 10:07 AM
streetinsider.com logopSivida (PSDV) Appoints New Chief Medical Officer (NASDAQ:PSDV)
www.streetinsider.com - August 3 at 10:14 AM
publicnow.com logopSivida Names Dario Paggiarino, M.D. as Chief Medical Officer (NASDAQ:PSDV)
www.publicnow.com - August 3 at 10:14 AM
publicnow.com logopSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis (NASDAQ:PSDV)
www.publicnow.com - August 1 at 7:11 AM
streetinsider.com logopSivida (PSDV) Reports First Medidur Phase 3 as PU Treatment Met ... - StreetInsider.com (NASDAQ:PSDV)
www.streetinsider.com - July 27 at 7:20 PM
capitalcube.com logopSivida Corp.: Strong price momentum but will it sustain? (NASDAQ:PSDV)
www.capitalcube.com - July 27 at 4:25 PM
globenewswire.com logoIncremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit (NASDAQ:PSDV)
globenewswire.com - July 27 at 9:59 AM
publicnow.com logopSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) (NASDAQ:PSDV)
www.publicnow.com - July 27 at 8:08 AM
news.cmlviz.com logopSivida Corp. Stock Volatility Hits An Unsually High Level - CML News (NASDAQ:PSDV)
news.cmlviz.com - July 20 at 7:48 PM
capitalcube.com logoETF’s with exposure to pSivida Corp. : July 20, 2016 (NASDAQ:PSDV)
www.capitalcube.com - July 20 at 12:50 PM
streetinsider.com logopSivida (PSDV) Announces Presentation of New Tethadur bioerodible Tech Data; Retained High Activity Noted - StreetInsider.com (NASDAQ:PSDV)
www.streetinsider.com - July 20 at 9:47 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for pSivida Corp. (NASDAQ:PSDV) - TGP (NASDAQ:PSDV)
telanaganapress.com - July 20 at 9:47 AM
finance.yahoo.com logoData Shows pSivida’s Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy (NASDAQ:PSDV)
finance.yahoo.com - July 20 at 8:00 AM
ftsenews.co.uk logoNew Broker Ratings For PSivida Corp. (PSDV) - FTSE News (NASDAQ:PSDV)
www.ftsenews.co.uk - July 19 at 7:04 PM
News IconBlazing Stocks Calls Bulls- Shaw Communications (NYSE:SJR), pSivida Corp. (NASDAQ:PSDV), HEALTHSOUTH ... - Seneca Globe (NASDAQ:PSDV)
www.senecaglobe.com - July 19 at 5:41 AM
biz.yahoo.com logoPSIVIDA CORP. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financ (NASDAQ:PSDV)
biz.yahoo.com - July 18 at 4:03 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For PSivida Corp. (PSDV) - Fiscal Standard (NASDAQ:PSDV)
www.fiscalstandard.com - July 17 at 11:06 AM
nasdaq.com logoPSivida To Locate Research And Product Development Activities In U.S. Facility (NASDAQ:PSDV)
www.nasdaq.com - July 15 at 5:57 PM
News IconFollowing Unusual Volume on Shares of pSivida Corp. (NASDAQ:PSDV) - Engelwood Daily (NASDAQ:PSDV)
www.engelwooddaily.com - July 15 at 12:04 PM
streetinsider.com logopSivida (PSDV) Says Investigator-Sponsored Phase 2 Study Results Show Medidur Fully Controlled Uveitis - StreetInsider.com (NASDAQ:PSDV)
www.streetinsider.com - July 15 at 12:04 PM
publicnow.com logopSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility (NASDAQ:PSDV)
www.publicnow.com - July 15 at 8:28 AM
globenewswire.com logoStudy Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology (NASDAQ:PSDV)
globenewswire.com - July 14 at 7:11 PM
publicnow.com logoInvestigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve (NASDAQ:PSDV)
www.publicnow.com - July 14 at 12:18 PM
finance.yahoo.com logo11:01 am pSivida announces the results from an investigator-sponsored Phase 2 study of Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the 2 years following implantation, while six of 10 fellow eyes without Me (NASDAQ:PSDV)
finance.yahoo.com - July 14 at 11:01 AM
finance.yahoo.com logoInvestigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve (NASDAQ:PSDV)
finance.yahoo.com - July 14 at 11:00 AM
News IconpSivida Corp. (NASDAQ:PSDV) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:PSDV)
telanaganapress.com - July 13 at 9:53 AM
ftsenews.co.uk logoPSivida Corp. (PSDV) Updated Price Targets - FTSE News (NASDAQ:PSDV)
www.ftsenews.co.uk - July 13 at 9:53 AM
news.cmlviz.com logoOption Market: pSivida Corp. Risk Hits An Elevated Level - CML News (NASDAQ:PSDV)
news.cmlviz.com - July 12 at 7:12 PM
News IconPsivida Corporation (NASDAQ:PSDV) Shorted Shares Increased 8.42% After Market Selling - Consumer Eagle (NASDAQ:PSDV)
www.consumereagle.com - July 12 at 7:12 PM
News IconCan pSivida Corp. (NASDAQ:PSDV) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:PSDV)
www.engelwooddaily.com - July 8 at 6:56 PM
News IconCompany Stock Focus for pSivida Corp. (NASDAQ:PSDV): Which Way Will Shares Head? - Press Telegraph (NASDAQ:PSDV)
presstelegraph.com - July 8 at 6:56 PM
fiscalstandard.com logoPSivida Corp. (PSDV) Current Analyst Ratings - Fiscal Standard (NASDAQ:PSDV)
www.fiscalstandard.com - July 8 at 6:56 PM
publicnow.com logopSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting (NASDAQ:PSDV)
www.publicnow.com - July 8 at 8:41 AM
News IconpSivida Corp. (NASDAQ:PSDV) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:PSDV)
telanaganapress.com - July 6 at 11:37 AM
News IconStock Trending Upwards in Trading: pSivida Corp. (NASDAQ:PSDV) - Telanagana Press (NASDAQ:PSDV)
telanaganapress.com - July 5 at 6:42 PM
News IconShare Performance Recap for: pSivida Corp. (NASDAQ:PSDV) - Press Telegraph (NASDAQ:PSDV)
presstelegraph.com - July 5 at 6:42 PM
News IconpSivida Corp. (NASDAQ:PSDV)'s Company Shares Decreased 15.95% After Low Volatility - Engelwood Daily (NASDAQ:PSDV)
www.engelwooddaily.com - July 5 at 6:42 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead PSivida Corp. (PSDV) - Fiscal Standard (NASDAQ:PSDV)
www.fiscalstandard.com - July 5 at 6:42 PM
globenewswire.com logoPromising Results for Potential Sustained Treatment of Wet AMD Using a TKI (NASDAQ:PSDV)
globenewswire.com - July 5 at 11:24 AM
streetinsider.com logopSivida (PSDV) Completes Two Preclinical Studies Utilizing Durasert Technology (NASDAQ:PSDV)
www.streetinsider.com - July 5 at 11:24 AM

Social

pSivida Corp. (NASDAQ:PSDV) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff